Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02914470 | Carboplatin-cyclophosphamide Combined With Atezolizumab(PROLOG) | completed | Phase 1 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2021 | clinicaltrials |
| NCT04453241 | Immunogenicity and Safety Study of NBP615 in Healthy Female | completed | Phase 1 / Phase 2 | 200 | SK Bioscience Co., Ltd.INDUSTRY | 1 | Oct 1, 2021 | clinicaltrials |
| NCT02058550 | Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy | completed | Phase 1 | 72 | Stanford UniversityOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT03394885 | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer(AdORN) | completed | Phase 1 / Phase 2 | 18 | Duke UniversityOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT00574678 | Analyzing the Composition of Tears to Identify Cancer(ACT) | completed | Phase 1 / Phase 2 | 150 | University of ArkansasOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT02270606 | Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer | completed | Phase 1 | 14 | Virginia Commonwealth UniversityOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03332576 | Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | completed | Phase 1 | 37 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT03359850 | Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients | completed | Phase 1 | 17 | Tesaro, Inc.INDUSTRY | 1 | May 28, 2021 | clinicaltrials |
| NCT02303912 | Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer(ProGem2) | completed | Phase 1 | 25 | Imperial College Healthcare NHS TrustOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT02028117 | Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients(OCTAVE) | completed | Phase 1 | 38 | Akamis BioINDUSTRY | 2 | May 13, 2021 | clinicaltrials |
| NCT03205176 | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | completed | Phase 1 | 49 | AstraZenecaINDUSTRY | 2 | May 6, 2021 | clinicaltrials |
| NCT02354534 | Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3) | completed | Phase 1 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02269293 | Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | completed | Phase 1 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT01065662 | AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | completed | Phase 1 | 11 | Susana M. Campos, MDOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT03813940 | Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) | completed | Phase 1 | 24 | Xiamen UniversityOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT03507543 | The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors | completed | Phase 1 | 39 | Impact Therapeutics, Inc.INDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03508011 | A Study of IMP4297 in Patients With Advanced Solid Tumors | completed | Phase 1 | 57 | Impact Therapeutics, Inc.INDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03213964 | Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int | completed | Phase 1 | 10 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT01322802 | Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer | completed | Phase 1 | 25 | University of WashingtonOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT01989546 | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | completed | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 | clinicaltrials |
| NCT02172911 | A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer | completed | Phase 1 / Phase 2 | 10 | Inovio PharmaceuticalsINDUSTRY | 1 | Feb 21, 2021 | clinicaltrials |
| NCT01623349 | Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | completed | Phase 1 | 118 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT00003450 | Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer | completed | Phase 1 | — | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT02179515 | Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) | completed | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2021 | clinicaltrials |
| NCT03697226 | Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection. | completed | Phase 1 | 8 | Antiva BiosciencesINDUSTRY | 1 | Jan 13, 2021 | clinicaltrials |
| NCT01338831 | Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer | completed | Phase 1 | 73 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT01068483 | Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients | completed | Phase 1 | 107 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 8, 2020 | clinicaltrials |
| NCT03790423 | 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer | completed | Phase 1 | 10 | Rigshospitalet, DenmarkOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT00765973 | Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors | completed | Phase 1 | 14 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT03704467 | Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer | completed | Phase 1 | 3 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 3 | Nov 13, 2020 | clinicaltrials |
| NCT03480750 | Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer(Trientine) | completed | Phase 1 / Phase 2 | 18 | National Cheng-Kung University HospitalOTHER | 0 | Nov 10, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT03101280 | A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer | completed | Phase 1 | 29 | Hoffmann-La RocheINDUSTRY | 4 | Oct 22, 2020 | clinicaltrials |
| NCT01935973 | Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2020 | clinicaltrials |
| NCT01649336 | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | completed | Phase 1 | 36 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Sep 14, 2020 | clinicaltrials |
| NCT03030287 | A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer | completed | Phase 1 | 44 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT01711515 | Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2020 | clinicaltrials |
| NCT02121990 | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 1 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT03158935 | The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial(ACTIVATE) | completed | Phase 1 | 8 | University Health Network, TorontoOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT02092363 | Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer | completed | Phase 1 | 37 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 12, 2020 | clinicaltrials |
| NCT03430518 | Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer | completed | Phase 1 | 9 | Amy TierstenOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT01263327 | Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine | completed | Phase 1 | 38 | Xiamen UniversityOTHER | 1 | Jul 10, 2020 | clinicaltrials |
| NCT01643499 | Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies | completed | Phase 1 | 79 | University of ChicagoOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT01580696 | Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer | completed | Phase 1 / Phase 2 | 51 | COL George Peoples, MD, FACSFED | 1 | May 4, 2020 | clinicaltrials |
| NCT01711970 | A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer | completed | Phase 1 / Phase 2 | 38 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT01831089 | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | completed | Phase 1 | 69 | PharmaMarINDUSTRY | 3 | Apr 10, 2020 | clinicaltrials |
| NCT00006036 | Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 14 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 6, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Oct 19, 2021source: clinicaltrials